National Comprehensive Cancer Network
October 6, 2017
Christopher K. Bichakjian, MD/Chair, Thomas Olencki, DO/Vice-Chair, Sumaira Z. Aasi, MD, Murad Alam, MD, James S. Andersen, MD, Rachel Blitzblau, MD, PhD, Glen M. Bowen, MD, Caro M. Contreras, MD, Gregory A. Daniels, MD, PhD, Roy Decker, MD, PhD, Jeffrey M. Farma, D, Kris Fisher, MD, Brian Gastman, MD, Karthik Ghosh, MD, Roy C. Grekin, MD, Kenneth Grossman, MD, PhD, Alan L. Ho, MD, PhD, Karl D. Lewis, MD, Manisha Loss, MD, Daniel D. Lydiatt, DDS, MD, Jane Messina, MD, Kishwer S. Nehal, MD, Paul Nghiem, MD, PhD, Igor Puzanov, MD, Chrysalyne D. Schmults, MD, Ashok R. Shaha, MD, Valencia Thomas, MD, Elise A. Olsen, MD, Chrysalyne D. Schmults, MD, Ashok R. Shaha, MD, Valencia Thomas, MD, Yaohui G. Xu MD, PhD, John A. Zic, MDDownload PDF
This updated version of the MCC Clinical Practice Guidelines has a new feature, ‘evidence blocks’, that summarize the efficacy, cost and quality of data that support the use of various therapies for MCC. This should help physicians and insurers to decide what therapies are indicated for patients in different situations.
The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
The authoritative source on Merkel cell carcinoma.
November 30, 2017